A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (TH V THL)

This study has been terminated.
(study closure to recruitment as of 2nd February)
Sponsor:
Information provided by (Responsible Party):
ICORG- All Ireland Cooperative Oncology Research Group
ClinicalTrials.gov Identifier:
NCT01526369
First received: February 1, 2012
Last updated: February 20, 2015
Last verified: February 2015
  Purpose

The proposed phase III randomised trial will compare the efficacy of trastuzumab and paclitaxel with trastuzumab, paclitaxel and lapatinib in first line treatment of HER2 positive metastatic breast cancer. The investigators will also examine potential predictive biomarkers of response to trastuzumab and lapatinib in pre-treatment biopsy samples and serum samples.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Trastuzumab
Drug: Paclitaxel
Drug: Lapatinib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by ICORG- All Ireland Cooperative Oncology Research Group:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 9 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 30 months ] [ Designated as safety issue: Yes ]

Enrollment: 75
Study Start Date: January 2012
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Paclitaxel and Trastuzumab
Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
Drug: Trastuzumab Drug: Paclitaxel
Experimental: Paclitaxel, Trastuzumab and Lapatinib

Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)

+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal.

Drug: Trastuzumab Drug: Paclitaxel Drug: Lapatinib

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent obtained prior to any study-related procedures
  2. Female age 18 years or greater.
  3. ECOG Performance Status of 0 or 1.
  4. Histologically or cytologically-confirmed invasive metastatic breast cancer.
  5. Patients must have measurable disease according to RECIST criteria Version 1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan,MRI, or calipers by clinical exam.
  6. Tumour shows HER2 over-expression (3+ by IHC and/or FISH + ) by testing of the primary tumour and if available the biopsied metastatic lesion
  7. Patients who received prior radiotherapy must have completed it at least 4 weeks before registration and recovered from all treatment-related toxicities.
  8. Cardiac ejection fraction within the institutional range of normal as measured by MUGA or ECHO within 14 days prior to registration. Note that baseline and on treatment scans should be performed using the same modality and preferably at the same institution.
  9. Adequate haematological, hepatic, and renal function.

    • Haemoglobin ≥ 9g/dL
    • Neutrophils (ANC/AGC) ≥1500/mm³ (1.5 x 10^9/L)
    • Platelets ≥ (100 x 10^9/L)
    • Total bilirubin ≤ 1.5mg/dL (25.65 μmol/L)
    • Both ALT (SGPT) and AST (SGOT) ≤ 3 x ULN with or without liver Metastasis
    • Alkaline phosphatase ≤ 2.5 x ULN
    • Serum creatinine ≤1.5 ULN or calculated creatinine clearance (CrCl) ≥ 30mL/min according to the Cockcroft and Gault formula (Appendix K)
  10. Able to swallow and retain oral medication.
  11. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Female patients of childbearing potential must have pregnancy excluded by urine or serum beta-HCG testing within 7 days prior to registration.
  12. Estimated life expectancy greater than 12 weeks

Exclusion Criteria:

  1. Prior systemic therapy for metastatic disease (except one line of hormonal therapy for metastatic disease without trastuzumab).
  2. Recurrence within 12 months from completion of adjuvant chemotherapy to the development of metastatic disease.
  3. Recurrence within 6 months from completion of adjuvant trastuzumab to the development of metastatic disease.
  4. Prior lapatinib treatment.
  5. Peripheral neuropathy ≥ grade 2
  6. Patients with known CNS metastasis should be excluded from this clinical trial
  7. Prior radiotherapy to more than half of the bony pelvis.
  8. Uncontrolled or symptomatic angina, uncontrolled arrhythmias, congestive heart failure, a documented MI within 6 months prior to registration or any other cardiac disorders, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient .
  9. Immediate or delayed hypersensitivity or untoward reaction to paclitaxel, trastuzumab, or other related compounds, or to drugs chemically related to lapatinib (including other anilinoquinazolines, e.g. gefitinib (Iressa®) and erlotinib (Tarceva®), or other chemically-related compounds).
  10. Pregnant or breastfeeding women are excluded from this study.
  11. Patients should not be receiving any other investigational agents (within 30 days prior to registration) or receiving concurrent anticancer therapy.
  12. Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors (Table 9).
  13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
  14. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
  15. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  16. Concurrent treatment with ovarian hormone replacement therapy. Prior treatment must be stopped prior to registration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01526369

  Hide Study Locations
Locations
Finland
Helsinki University Hopsital
Helsinki, Finland
Kuopio University hospital
Kuopio, Finland
France
CRLC Val d'Aurelle
Montpellier, France
Germany
Interdisziplinäre Onkologische Zentrum München (IOZ München)
Munich, Germany
Ireland
St Vincent's University Hospital
Dublin, Leinster, Ireland
Cork University Hospital
Cork, Ireland
St James's Hospital
Dublin, Ireland
Mater Misericordiae University Hospital
Dublin, Ireland
Mater Private Hospital
Dublin, Ireland
Beaumont Hospital
Dublin, Ireland
University Hospital Galway
Galway, Ireland
Midwestern Regional Hospital
Limerick, Ireland
Sligo General Hospital
Sligo, Ireland
Waterford Regional Hospital
Waterford, Ireland
Israel
Rabin Medical Center
Petah Tikva, Israel
The Chaim Sheba Medical Center
Tel Hashomer, Israel
Norway
Oslo University Hopsital
Oslo, Norway
Portugal
Hospital Santa Maria
Lisbon, Portugal
Spain
Complejo Hospitalario de Jaen
Andalucia, Spain
Hospital Nuestra Senora de Sonsoles
Avila, Spain
Hospital Infanta Cristina
Badajoz, Spain
Hospital Universitario de Canarias
Canarias, Spain
Hospital Universitari Arnau de Vilanova de Lleida
Cataluna, Spain
Hospital Virgen de la Luz
Cuenca, Spain
Centro Oncologico de Galicia
Galicia, Spain
Hospital General de Grannollers
Granollers, Spain
Complejo Hospitalario Xeral Calde / Hospital Lucus Augusti
Lugo, Spain
H. Puerta de Hierro
Madrid, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital de Mataro
Mataro, Spain
Hospital Donostia
Pais Vasco, Spain
Hospital Infanta Cristina
Parla, Spain
Hospital General Universitario de Elche
Valencia, Spain
Hospital General Universitario de Valencia
Valencia, Spain
Hospital Clinico Universitario 'Lozano Blesa'
Zaragoza, Spain
Sponsors and Collaborators
ICORG- All Ireland Cooperative Oncology Research Group
  More Information

No publications provided

Responsible Party: ICORG- All Ireland Cooperative Oncology Research Group
ClinicalTrials.gov Identifier: NCT01526369     History of Changes
Other Study ID Numbers: ICORG 11-10
Study First Received: February 1, 2012
Last Updated: February 20, 2015
Health Authority: Ireland: Irish Medicines Board

Keywords provided by ICORG- All Ireland Cooperative Oncology Research Group:
HER2-positive metastatic breast cancer.

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Lapatinib
Paclitaxel
Trastuzumab
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on April 23, 2015